Coll, ElisabethFernandez-Ruiz, MarioSanchez-Alvarez, J EmilioMartinez-Fernandez, Jose RCrespo, MartaGayoso, JorgeBada-Bosch, TeresaOppenheimer, FedericoMoreso, FrancescLopez-Oliva, Maria OMelilli, EdoardoRodriguez-Ferrero, Marisa LBravo, CarlosBurgos, ElenaFacundo, CarmeLorenzo, InmaculadaYañez, IñigoGaleano, CristinaRoca, AnaCabello, MercedesGomez-Bueno, ManuelGarcia-Cosio, MªDoloresGraus, JavierLlado, Laurade Pablo, AliciaLoinaz, CarmeloAguado, BeatrizHernandez, DomingoDominguez-Gil, BeatrizSpanish Group for the Study of COVID-19 in Transplant Recipients2023-02-092023-02-092020-10-9Coll E, Fernández-Ruiz M, Sánchez-Álvarez JE, Martínez-Fernández JR, Crespo M, Gayoso J, et al.; Spanish Group for the Study of COVID-19 in Transplant Recipients. COVID-19 in transplant recipients: the Spanish experience. Am J Transplant. 2021 May;21(5):1825-1837http://hdl.handle.net/10668/16472We report the nationwide experience with solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) recipients diagnosed with coronavirus disease 2019 (COVID-19) in Spain until 13 July 2020. We compiled information for 778 (423 kidney, 113 HSCT, 110 liver, 69 heart, 54 lung, 8 pancreas, 1 multivisceral) recipients. Median age at diagnosis was 61 years (interquartile range [IQR]: 52-70), and 66% were male. The incidence of COVID-19 in SOT recipients was two-fold higher compared to the Spanish general population. The median interval from transplantation was 59 months (IQR: 18-131). Infection was hospital-acquired in 13% of cases. No donor-derived COVID-19 was suspected. Most patients (89%) were admitted to the hospital. Therapies included hydroxychloroquine (84%), azithromycin (53%), protease inhibitors (37%), and interferon-β (5%), whereas immunomodulation was based on corticosteroids (41%) and tocilizumab (21%). Adjustment of immunosuppression was performed in 85% of patients. At the time of analysis, complete follow-up was available from 652 patients. Acute respiratory distress syndrome occurred in 35% of patients. Ultimately, 174 (27%) patients died. In univariate analysis, risk factors for death were lung transplantation (odds ratio [OR]: 2.5; 95% CI: 1.4-4.6), age >60 years (OR: 3.7; 95% CI: 2.5-5.5), and hospital-acquired COVID-19 (OR: 3.0; 95% CI: 1.9-4.9).enantibiotic: antiviralclinical decision-makingclinical research/practicecomplication: infectiousinfection and infectious agents - viralinfectious diseaseCOVID-19FemaleHematopoietic Stem Cell TransplantationHumansMaleMiddle AgedOrgan TransplantationSARS-CoV-2SpainTransplant Recipientsresearch article33098200open accessAnti-Bacterial AgentsAntiviral AgentsClinical Decision-MakingCommunicable DiseasesInfections10.1111/ajt.163691600-6143http://repositori.upf.edu/bitstream/10230/47594/1/coll-ajt-covi.pdf